# Combined PD1 Inhibitor and Decitabine in Elderly Patients With Relapse and Refractory Acute Myeloid Leukemia

> **NCT04353479** · PHASE2 · UNKNOWN · sponsor: **Shanghai Jiao Tong University School of Medicine** · enrollment: 29 (estimated)

## Conditions studied

- Acute Myeloid Leukemia

## Interventions

- **DRUG:** Camrelizumab(SHR-1210)
- **DRUG:** Decitabine

## Key facts

- **NCT ID:** NCT04353479
- **Lead sponsor:** Shanghai Jiao Tong University School of Medicine
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2020-04-25
- **Primary completion:** 2020-12-31
- **Final completion:** 2022-12-31
- **Target enrollment:** 29 (ESTIMATED)
- **Last updated:** 2020-04-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04353479

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04353479, "Combined PD1 Inhibitor and Decitabine in Elderly Patients With Relapse and Refractory Acute Myeloid Leukemia". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04353479. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*